Abzena Group

Website:
www.abzena.com
Organisation type
Dr Donna Hackett
VP Intellectual Property, Commercial and Legal Affairs 
Mr John Burt
CEO 
Dr George Badescu
Director, Scientific Affairs 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.

BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.

Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.

CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.

Keywords
product development,regulatory,consultancy
Membership affiliation
Organisation type
Mr Russell Neal
Managing Director 
Ms Megan Hill
Business Development Manager 

Domainex Ltd

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates.

Membership affiliation
Organisation type
Dr Edward Littler
CEO 

Isogenica Ltd

Membership affiliation
Organisation type
Dr Ajay Mistry
BD 
Dr Neil Cooley
COO 

NeRRe Therapeutics Ltd

Membership affiliation
Organisation type
Dr Mike Trower
Chief Operating Officer 
Mr Ian Nicholson
Chief Business Officer 

P.A.S.M. Motteram

Keywords
clinical trials,consultancy
Membership affiliation
Organisation type
Mr Peter Motteram
Director 

Sigma-Aldrich Company Ltd

Website:
www.sial.com
Membership affiliation
Organisation type
Dr Chris Worrall
NA Business Development Manager 

SYNthesis med chem

Membership affiliation
Organisation type
Mr Simon Bury
Head of Business Development 
Professor Andrew Wilks
Chairman